Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PEP-CMV

Phase 2Biologic

UUniversity of Florida

PEP-CMV is one of 39 biologic programs targeting High Grade Glioma. It is currently in Phase 2.

2

Indications

3

Total Trials

2

Active Trials

38

Competitors

Pipeline

Status by Indication[3][1]

Indication

High Grade GliomaRecruiting

Malignant GliomaActive, not recruiting

High Grade GliomaPhase 2

Recruiting

Malignant GliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Malignant Glioma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Afinitor

Norvir

Plaquenil

Jazz Pharmaceuticals

Lynparza

Levulan

Sun Pharmaceutical Industries, Inc.

Ziagen

Tafinlar

Aloxi

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

High Grade Glioma

NCT05096481

Clinical

Trials by Indication[1]

Glioblastoma1 trial

Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens

Withdrawn·UUniversity of Florida·Phase 1·NCT01854099

Malignant Glioma1 trial

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

Active, not recruiting·DDaniel Landi·Phase 1·NCT03299309·30 enrolled

High Grade Glioma1 trial

Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05096481·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PEP-CMV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEP-CMV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEP-CMV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Florida

Related News